Effects of Aromatase Inhibitors on Bone Health in Postmenopausal Women
Author Information
Author(s): Goss Paul E, Hadji Peyman, Subar Milayna, Abreu Paula, Thomsen Torben, Banke-Bochita Jose
Primary Institution: Massachusetts General Hospital
Hypothesis
This study was designed to compare the effects of exemestane with the nonsteroidal aromatase inhibitors anastrozole and letrozole on serum and urine levels of biomarkers of bone turnover in healthy postmenopausal women.
Conclusion
Exemestane increased serum levels of the bone-formation marker PINP after 24 weeks, suggesting a specific bone-formation effect related to its androgenic structure.
Supporting Evidence
- Exemestane treatment resulted in a significant increase in the bone-formation marker PINP compared to other treatments.
- Bone-resorption markers increased in all treatment groups, but the increase was lower for anastrozole.
- Exemestane was the only aromatase inhibitor that consistently increased levels of PINP.
Takeaway
This study looked at how different medications for breast cancer affect bones in older women. It found that one medicine, exemestane, helps bones more than the others.
Methodology
The study involved 84 healthy postmenopausal women who were randomized to receive exemestane, letrozole, anastrozole, or placebo for 24 weeks, with assessments of bone turnover markers at various time points.
Potential Biases
Potential bias due to the exploratory nature of the study and the small sample size.
Limitations
The study had a small sample size and was of short duration, which may limit the generalizability of the findings.
Participant Demographics
All participants were white women aged 50 to 75 years who had experienced natural menopause.
Statistical Information
P-Value
0.024
Confidence Interval
95% CI, 11–30%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website